ILDR2 antagonists and combinations thereof

US11655297B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE
• Compugen Ltd. · IL

Inventors

• Lars Röse · Berlin, DE
• Uwe Gritzan · Cologne, DE
• Julia Hütter · Berlin, DE
• Spencer Liang · San Mateo, US
• Andrew James Pow · Burlingame, US
• John Hunter · South Holland, US
• Ofer Levy · Afula, IL
• Ilan Vaknin · Nes Ziona, IL

Key dates

• Filing date: Nov 28, 2018
• Grant date: May 23, 2023
• Expiry date: Jun 20, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.